IMO 2055

Drug Profile

IMO 2055

Alternative Names: EMD 1201081; HYB-2055; IMO-2055; IMOxine; TLR9 immunomodulator

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Idera Pharmaceuticals
  • Developer Idera Pharmaceuticals; Merck KGaA
  • Class Antineoplastics; Oligonucleotides
  • Mechanism of Action Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Colorectal cancer; Head and neck cancer; Non-small cell lung cancer

Highest Development Phases

  • Preclinical Cancer
  • Suspended Colorectal cancer; Non-small cell lung cancer
  • No development reported Head and neck cancer
  • Discontinued Asthma; Renal cell carcinoma

Most Recent Events

  • 04 Aug 2015 No recent reports on development identified - Phase-II for Head and neck cancer (Combination therapy, Metastatic disease, Recurrent, Second-line therapy or greater) in USA, Belgium, Czech Republic, France, Hungary, United Kingdom, Slovakia and Poland (SC)
  • 02 Dec 2014 Final pharmacodynamics data from preclinical models of bladder, colon, and lung cancer released by Idera Pharmaceuticals
  • 01 Jun 2014 Preclinical trials in Cancer in USA (Intratumoural)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top